Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05283382 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cannabidiol Effects on Learning and Anxiety

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 30, 2025 to Dec 30, 2026
    • Study completion date: Feb 2026 to Feb 2027
    v7
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 28, 2024 to Oct 30, 2024
    v6
  3. Study sites: 1 to 0v5
  4. Primary completion date: Dec 30, 2024 to Dec 30, 2025
    • Start date: Feb 1, 2024 to Oct 28, 2024
    • Study sites: 0 to 1
    • Study completion date: Feb 1, 2025 to Feb 2026
    v4
  5. Primary completion date: Dec 2022 to Dec 30, 2024
    • Start date: Sep 1, 2022 to Feb 1, 2024
    • Study completion date: Dec 2022 to Feb 1, 2025
    v3
  6. Start date: Apr 2022 to Sep 1, 2022v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.
Trial Details
NCT Number NCT05283382
Lead Sponsor University of Connecticut
Conditions
(from sponsor)		 Anxiety and Fear
Related terms Anxiety Disorders
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov